摘要
目的:探讨信迪利单抗与卡瑞丽珠单抗分别辅助肺癌患者化疗的效果。方法:选取我院2019年3月—2022年3月收治的80例肺癌患者作为研究对象,根据药物类型分成信迪利单抗组与卡瑞丽珠单抗组,每组40例。信迪利单抗组采用信迪利单抗联合常规化疗治疗,卡瑞丽珠单抗组采用卡瑞丽珠单抗联合常规化疗治疗。比较两组临床效果、血清肿瘤标志物、免疫功能变化情况以及生活质量评分。结果:信迪利单抗组客观缓解率、疾病控制率与卡瑞丽珠单抗组比较,差异无统计学意义(P>0.05);卡瑞丽珠单抗组CYFRA21-1、CA125、CEA水平高于信迪利单抗组(P<0.05);卡瑞丽珠单抗组与信迪利单抗组CD4^(+)、CD3^(+)、CD4^(+)/CD8^(+)比较,差异无统计学意义(P>0.05);信迪利单抗组生活质量评分高于卡瑞丽珠单抗组(P<0.05)。结论:治疗肺癌患者时,在常规化疗基础上采用信迪利单抗或卡瑞丽珠单抗均有较好的治疗效果,可有效降低体内肿瘤标志物表达水平,提升免疫功能,但信迪利单抗患者生活质量评分更高一些。
Objective: To investigate the effect of chemotherapies combined with Sindili monoclonal antibody and Calorie monoclonal antibody on patients with lung cancer. Methods: A total of 80 patients with lung cancer admitted to our hospital from March 2019 to March 2022 were selected as the study subjects. According to the type of drug, they were divided into the sintilizumab group and the carirelizumab group, with 40 cases in each group. The patients in the xindili monoclonal antibody group were treated with xindili monoclonal antibody combined with conventional chemotherapy, and the patients in the carilli monoclonal antibody group were treated with carilli monoclonal antibody combined with conventional chemotherapy. The clinical effects, serum tumor markers, immune function changes and quality of life scores were compared between the two groups. Results: There was no significant difference in objective remission rate and disease control rate between sindilizumab group and carrelizumab group(P>0.05). The levels of CYFRA21-1, CA125 and CEA in carrelizumab group were higher than those in sindilizumab group(P<0.05). There was no significant difference in CD4^(+), CD3^(+), CD4^(+)/CD8^(+)between carrelizumab group and sindilizumab group(P>0.05). The quality of life score of sindilizumab group was higher than that of carrelizumab group(P<0.05). Conclusion: In the treatment of lung cancer patients, the use of sindilizumab or carrelizumab on the basis of conventional chemotherapy has a good therapeutic effect, which can effectively reduce the expression level of tumor markers in the body and improve immune function, but the quality of life score of patients with sindilizumab is higher.
作者
马晓艳
张桂芳
MA Xiaoyan;ZHANG Guifang(Department of Internal Medicine-Oncology,Xinxiang Central Hospital/the Fourth Clinical College of Xinxiang Medical College,Xinxiang 453000,Henan,China)
出处
《中国药物滥用防治杂志》
CAS
2022年第12期1820-1823,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
作者简介
马晓艳(1983.06-),女,汉族,河南驻马店人,硕士,主治医师,主要研究方向:肺癌等实体瘤的诊治;通信作者:张桂芳(1964.11-),女,汉族,河南武陟人,本科,主任医师,主要研究方向:恶性实体瘤的基础与临床研究。
